LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

1.63 -24.54

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.63

Max

1.63

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+436.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-17M 530M
Eelmine avamishind	26.17
Eelmine sulgemishind	1.63

Uudiste sentiment

By Acuity

11%

89%

10 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. veebr 2026, 17:37 UTC

Omandamised, ülevõtmised, äriostud

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20. veebr 2026, 16:18 UTC

Suurimad hinnamuutused turgudel

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20. veebr 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20. veebr 2026, 22:12 UTC

Tulu

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. veebr 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

20. veebr 2026, 21:23 UTC

Tulu

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20. veebr 2026, 21:20 UTC

Market Talk

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20. veebr 2026, 21:01 UTC

Omandamised, ülevõtmised, äriostud

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20. veebr 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20. veebr 2026, 20:17 UTC

Market Talk

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20. veebr 2026, 20:11 UTC

Market Talk

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20. veebr 2026, 19:59 UTC

Market Talk

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20. veebr 2026, 19:58 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20. veebr 2026, 19:49 UTC

Market Talk

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20. veebr 2026, 19:09 UTC

Market Talk

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20. veebr 2026, 19:00 UTC

Market Talk

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20. veebr 2026, 18:28 UTC

Market Talk

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20. veebr 2026, 18:20 UTC

Market Talk

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20. veebr 2026, 18:05 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. veebr 2026, 18:04 UTC

Market Talk

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20. veebr 2026, 17:38 UTC

Market Talk

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20. veebr 2026, 17:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. veebr 2026, 17:24 UTC

Market Talk

Correction to Treasury Yields Fall Market Talk

20. veebr 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

20. veebr 2026, 16:53 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

20. veebr 2026, 16:53 UTC

Market Talk

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20. veebr 2026, 16:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. veebr 2026, 16:45 UTC

Market Talk

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20. veebr 2026, 16:40 UTC

Market Talk

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

436.97% tõus

12 kuu keskmine prognoos

Keskmine 11.33 USD 436.97%

Kõrge 15 USD

Madal 9 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

10 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.